Neither vortioxetine dose achieved a statistically significant improvement over placebo on the primary endpoint ( least-squares mean differencestandard error from placebo : -@ -LSB- p = @ -RSB- for @ mg and -@ -LSB- p = @ -RSB- for @mg vortioxetine ) or on any secondary efficacy endpoints .